3 not yet recruiting, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 3 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Ph+ Acute Lymphoblastic Leukemia (Ph+ALL): new trials by email Literature Review of Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) trials Research Report on Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2026-10-12 | 2026-09-25 |
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Not yet recruiting | The University of Hong Kong | 45 | 2026-03-30 | 2026-03-25 |
| Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation. - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2024-11-01 | 2024-10-26 |
| Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies ETC-1907206, dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Phase 1 | Withdrawn | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | 2018-04-25 | 2018-10-25 |
Leukemia, Myeloid, Accelerated Phase (1)
Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Dasatinib (2) · Imatinib Mesylate (1) · Inotuzumab Ozogamicin (1) · blinatumomab (1) · nilotinib (1) · olverembatinib (1) · venetoclax (1)
Institute of Hematology & Blood Diseases Hospital, China (2) · EDDC (Experimental Drug Development Centre), A*STAR Research Entities (1) · The University of Hong Kong (1)
China (1) · Hong Kong (1) · Singapore (1) · United States (1)